SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 229 filers reported holding SANGAMO THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.52 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $199,000 | -85.3% | 26,500 | -82.3% | 0.00% | -100.0% |
| Q3 2021 | $1,352,000 | -60.5% | 150,000 | -47.6% | 0.00% | -66.7% |
| Q2 2021 | $3,424,000 | +257.8% | 286,000 | +274.7% | 0.00% | +200.0% |
| Q1 2021 | $957,000 | -20.8% | 76,321 | -1.4% | 0.00% | 0.0% |
| Q4 2020 | $1,208,000 | +84.4% | 77,420 | +11.8% | 0.00% | – |
| Q3 2020 | $655,000 | +42.1% | 69,232 | +61.4% | 0.00% | – |
| Q2 2019 | $461,000 | -66.3% | 42,900 | -64.0% | 0.00% | -100.0% |
| Q4 2018 | $1,369,000 | -32.5% | 119,217 | -0.3% | 0.00% | 0.0% |
| Q3 2018 | $2,027,000 | -45.6% | 119,600 | -54.4% | 0.00% | -60.0% |
| Q2 2018 | $3,727,000 | +375.4% | 262,468 | +449.0% | 0.01% | +400.0% |
| Q4 2017 | $784,000 | +49.3% | 47,810 | +36.6% | 0.00% | 0.0% |
| Q3 2017 | $525,000 | +70.5% | 35,000 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $308,000 | -54.4% | 35,000 | -76.0% | 0.00% | 0.0% |
| Q3 2016 | $675,000 | +457.9% | 145,800 | +1234.9% | 0.00% | – |
| Q2 2015 | $121,000 | – | 10,922 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 6,000,000 | $66,540,000 | 6.69% |
| FIC CAPITAL INC | 787,529 | $8,734,000 | 3.47% |
| RA Capital Management | 1,220,209 | $13,532,000 | 1.36% |
| PRINCETON CAPITAL MANAGEMENT INC | 114,120 | $1,266,000 | 0.67% |
| Perceptive Advisors | 800,000 | $8,872,000 | 0.53% |
| Cormorant Asset Management, LP | 361,000 | $4,003,000 | 0.53% |
| Highlander Capital Management, LLC | 43,500 | $482,000 | 0.43% |
| APEX CAPITAL, LLC | 439,900 | $4,878,000 | 0.42% |
| WASATCH ADVISORS LP | 3,091,386 | $34,283,000 | 0.37% |
| Baker Brothers Advisors | 3,230,932 | $35,831,000 | 0.31% |